Enhances connectivity to HIS and EMR solutions
BOTHELL, Wash., Oct. 2 /PRNewswire-FirstCall/ -- Cardiac Science Corporation, (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products, announced today the launch of the Quinton Q-Tel RMS(R) 3.0. This significant advance to the trusted Quinton line of cardiac rehabilitation systems offers several connectivity upgrades and workflow advancements to enable the best possible treatment decisions in cardiac rehabilitation.
Some of the Q-Tel 3.0 key advancements include:
-- Bi-directional connectivity to a hospital's EMR and HIS system.
-- Improved tracking of HIPAA compliance requirements through user
-- Session Recovery advancements to prevent the loss of patient data due
to power interruption or application error.
-- Q-Tel Pocket Assistant for wireless session management, enabling users
to customize data entry parameters and formats for resting, exercise
and recovery data by program type.
"Quinton Q-Tel connects the clinician to the enterprise EMR, the patient, the medical staff and the latest technology," said Rene Mitchell, director of diagnostic marketing at Cardiac Science. "In addition to offering nurses and exercise physiologists the reliable, high-performance rehab technology they have come to expect from the Q-Tel system, Q-Tel 3.0 improves workflow efficiency with enhanced connectivity, allowing the rehab department to connect to the hospital's HIS and EMR system. These enhancements were in direct response to our customers' feedback on what would enable them to make the best possible treatment decisions, and manage their workflow most effectively."
Frost & Sullivan, the global growth consulting company, has awarded Cardiac Science its 2007 award for Global Excellence in ECG Monitoring, recognizing Cardiac Science's superior leadership and vision to provide superior healthcare solutions in the cardiac monitoring market.
For more information about the Q-Tel RMS 3.0 System, please call 800.679.8703.
About Cardiac Science Corporation
Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor -- defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China; Copenhagen, Denmark; and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that our Q-Tel RMS 3.0 and other products will be successful in the marketplace, resulting in increasing revenues and profits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the 10-k filed by Cardiac Science Corporation for the year ended December 31, 2006.
The statements in this press release speak as of the date of the release, and Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Cardiac Science Corporation
Sr. Vice President and CFO
EVC Group, Inc.
Douglas Sherk/Jenifer Kirtland
EVC Group, Inc.
|SOURCE Cardiac Science Corporation|
Copyright©2007 PR Newswire.
All rights reserved